These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15217940)

  • 1. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.
    de Jong FA; Mathijssen RH; Xie R; Verweij J; Sparreboom A
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4068-71. PubMed ID: 15217940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.
    Mathijssen RH; Verweij J; de Jonge MJ; Nooter K; Stoter G; Sparreboom A
    J Clin Oncol; 2002 Jan; 20(1):81-7. PubMed ID: 11773157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
    Klein CE; Gupta E; Reid JM; Atherton PJ; Sloan JA; Pitot HC; Ratain MJ; Kastrissios H
    Clin Pharmacol Ther; 2002 Dec; 72(6):638-47. PubMed ID: 12496745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
    de Jonge MJ; Verweij J; de Bruijn P; Brouwer E; Mathijssen RH; van Alphen RJ; de Boer-Dennert MM; Vernillet L; Jacques C; Sparreboom A
    J Clin Oncol; 2000 Jan; 18(1):195-203. PubMed ID: 10623710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
    Thompson PA; Gupta M; Rosner GL; Yu A; Barrett J; Bomgaars L; Bernstein ML; Blaney SM; Mondick J
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1027-37. PubMed ID: 18278496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
    Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
    Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
    Gajjar A; Chintagumpala MM; Bowers DC; Jones-Wallace D; Stewart CF; Crews KR
    Cancer; 2003 May; 97(9 Suppl):2374-80. PubMed ID: 12712459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G].
    Valenzuela Jiménez B; González Sales M; Escudero Ortiz V; Martínez Navarro E; Pérez Ruixo C; Rebollo Liceaga J; González Manzano R; Pérez Ruixo JJ
    Farm Hosp; 2013; 37(2):111-27. PubMed ID: 23789755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
    van Erp NP; Baker SD; Zhao M; Rudek MA; Guchelaar HJ; Nortier JW; Sparreboom A; Gelderblom H
    Clin Cancer Res; 2005 Nov; 11(21):7800-6. PubMed ID: 16278402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.
    Poujol S; Bressolle F; Duffour J; Abderrahim AG; Astre C; Ychou M; Pinguet F
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):292-305. PubMed ID: 16369821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of irinotecan metabolism by ketoconazole.
    Kehrer DF; Mathijssen RH; Verweij J; de Bruijn P; Sparreboom A
    J Clin Oncol; 2002 Jul; 20(14):3122-9. PubMed ID: 12118026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.
    Xiang X; Jada SR; Li HH; Fan L; Tham LS; Wong CI; Lee SC; Lim R; Zhou QY; Goh BC; Tan EH; Chowbay B
    Pharmacogenet Genomics; 2006 Sep; 16(9):683-91. PubMed ID: 16906022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
    Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
    Crews KR; Stewart CF; Jones-Wallace D; Thompson SJ; Houghton PJ; Heideman RL; Fouladi M; Bowers DC; Chintagumpala MM; Gajjar A
    Clin Cancer Res; 2002 Jul; 8(7):2202-9. PubMed ID: 12114421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
    Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
    Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
    Canal P; Gay C; Dezeuze A; Douillard JY; Bugat R; Brunet R; Adenis A; Herait P; Lokiec F; Mathieu-Boue A
    J Clin Oncol; 1996 Oct; 14(10):2688-95. PubMed ID: 8874328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.
    Smorenburg CH; Sparreboom A; Bontenbal M; Stoter G; Nooter K; Verweij J
    J Clin Oncol; 2003 Jan; 21(2):197-202. PubMed ID: 12525510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors.
    Marier JF; Pheng L; Trinh MM; Burris HA; Jones S; Anderson K; Warner S; Porubek D
    J Pharm Sci; 2011 Oct; 100(10):4536-45. PubMed ID: 21630281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
    Schaaf LJ; Hammond LA; Tipping SJ; Goldberg RM; Goel R; Kuhn JG; Miller LL; Compton LD; Cisar LA; Elfring GL; Gruia G; McGovren JP; Pirotta N; Yin D; Sharma A; Duncan BA; Rothenberg ML
    Clin Cancer Res; 2006 Jun; 12(12):3782-91. PubMed ID: 16778106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.